RKDA on Nasdaq
Arcadia Biosciences (United States)
Logo: Arcadia Biosciences, Public domain, via Wikimedia Commons4
Company based in the state of California, United States
Arcadia Biosciences (Nasdaq: RKDA) is a publicly traded American agricultural biotechnology headquartered in Davis, California focused on the development of traits to enhance crop quality and productivity. The company is partly owned by Moral Compass Corporation.3 From Wikipedia, CC BY-SA 4.0
Price unavailable
Last updated Oct 16, 2026.
Overview
2002Founded1
Compare with SPINDLETOP OIL & GAS CO, Viking Global Technologies, Inc. or MEXCO ENERGY CORP, or pick any stock.
- TickerRKDA on Nasdaq1
- IndustryCrude Petroleum & Natural Gas1
- HeadquartersDavis1
- Websitewww.arcadiabio.com
- Legal formcompany1
- Incorporated inDE5
- Business address5956 Sherry Lane, Suite 2000, Dallas, Tx5
- Filer categoryNon-accelerated filer, Smaller reporting company5
See how the biggest companies compare on our leaderboards
Arcadia Biosciences (Nasdaq: RKDA) is a publicly traded American agricultural biotechnology headquartered in Davis, California focused on the development of traits to enhance crop quality and productivity. The company is partly owned by Moral Compass Corporation.3
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-51.5%Operating margin6
-48.1%Net margin6
-3.7%Revenue growth, 20256
-56.5%Return on equity6
-$4.7MFree cash flow7
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue31¢$3.1M
- Research and development0¢$9.0K
- Selling, general and admin69¢$7.0M
- Income tax0¢$8.0K
Out of $4.9M in revenue.6 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.6
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total revenues | $4.9M | $5.0M |
| Cost of revenues | $3.1M | $3.0M |
| Research and development | $9.0K | $53.0K |
| Gain on sale of intangible assets | -$750.0K | -$4.0M |
| Impairment of property and equipment | $0 | $36.0K |
| Change in fair value of contingent consideration | -$2.0M | $0 |
| Selling, general and administrative | $7.0M | $9.6M |
| Total operating expenses | $7.4M | $8.7M |
| Loss from operations | -$2.5M | -$3.6M |
| Interest income | $221.0K | $782.0K |
| Credit loss | -$4.7M | $0 |
| Other income, net | $2.3M | $31.0K |
| Change in fair value of common stock warrant and option liabilities | $2.4M | -$1.5M |
| Net loss from continuing operations before income taxes | -$2.3M | -$4.3M |
| Income tax expense | -$8.0K | -$8.0K |
| Net loss from continuing operations | -$2.3M | -$4.3M |
| Net loss attributable to common stockholders | -$2.3M | -$7.0M |
| Basic net loss per share attributable to common stockholders from continuing operations | -$2 | -$3 |
| Diluted net loss per share attributable to common stockholders from continuing operations | -$2 | -$3 |
| Basic net loss per share attributable to common stockholders from discontinued operations | $0 | -$2 |
| Diluted net loss per share attributable to common stockholders from discontinued operations | $0 | -$2 |
| Net loss per basic share attributable to common stockholders | -$1.71 | -$5.17 |
| Net loss per diluted share attributable to common stockholders | -$1.71 | -$5.17 |
| Weighted average shares - Basic | 1.4M shares | 1.4M shares |
| Weighted average shares - Diluted | 1.4M shares | 1.4M shares |
| Unrealized gains on available-for-sale securities | $0 | $127.0K |
| Reclassification adjustment for gains on available-for-sale securities included in net loss | $0 | -$228.0K |
| Change in unrealized gains on available-for-sale securities | $0 | -$101.0K |
| Comprehensive loss | -$2.3M | -$7.1M |
Every line of the balance sheet in the latest annual report, as filed.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $259.0K | $4.2M | |
| Short-term investments | $4.3M | $0 | |
| Accounts receivable and other receivables, net of allowance for credit loss of $559 and $0 as of December 31, 2025 and 2024, respectively | $425.0K | $1.2M | $506.0K |
| Inventories | $1.2M | $904.0K | |
| Note receivable - current, net of allowance for credit losses (Note 8) | $0 | $1.9M | |
| Prepaid expenses and other current assets | $156.0K | $931.0K | |
| Current assets of discontinued operations - GoodWheat | $0 | $96.0K | |
| Total current assets | $6.4M | $9.2M | |
| Property and equipment, net | $8.0K | $41.0K | |
| Right of use assets | $0 | $137.0K | |
| Intangible assets, net | $39.0K | $39.0K | |
| Note receivable - noncurrent, net of allowance for credit losses (Note 8) | $0 | $4.0M | |
| Other noncurrent assets | $143.0K | $92.0K | |
| Total assets | $6.5M | $13.5M | |
| Accounts payable and accrued expenses | $1.8M | $2.1M | |
| Operating lease liability - current | $0 | $155.0K | |
| Total current liabilities | $2.1M | $2.6M | |
| Common stock warrant and option liabilities | $347.0K | $2.7M | |
| Other noncurrent liabilities | $0 | $2.0M | |
| Total liabilities | $2.4M | $7.3M | |
| Common stock, $0.001 par value -150,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 1,373,120 and 1,364,940 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively. | $65.0K | $65.0K | |
| Additional paid-in capital | $285.3M | $285.0M | |
| Accumulated deficit | -$281.2M | -$278.9M | |
| Total stockholders' equity | $4.1M | $6.2M | $12.7M |
| Total liabilities and stockholders equity | $6.5M | $13.5M | |
| Allowance for credit losses | $559.0K | $0 | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, authorized | 150.0M shares | 150.0M shares | |
| Common stock, issued | 1.4M shares | 1.4M shares | |
| Common stock, outstanding | 1.4M shares | 1.4M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.6
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$2.3M | -$7.0M |
| Change in fair value of common stock warrant and option liabilities | -$2.4M | $1.5M |
| Change in fair value of contingent consideration | -$2.0M | |
| Depreciation | $32.0K | $113.0K |
| Lease amortization | $122.0K | $652.0K |
| Amortization of note receivable discount | -$69.0K | -$157.0K |
| Gain on disposal of property and equipment | $0 | -$65.0K |
| Gain on sale of intangible assets | -$750.0K | -$4.0M |
| Gain on receipt of Above Food Ingredients, Inc. common stock | -$1.1M | $0 |
| Unrealized gain subsequent to receipt of Above Food Ingredients, Inc. common stock | -$1.2M | $0 |
| Stock-based compensation | $234.0K | $512.0K |
| Credit loss | $4.7M | $0 |
| Write-down of inventories | $0 | $154.0K |
| Impairment of property and equipment | $0 | $36.0K |
| Write-down of non-controlling interest | $0 | $138.0K |
| Accounts receivable and other receivables | $165.0K | -$762.0K |
| Inventories | -$308.0K | $550.0K |
| Prepaid expenses and other current assets | $775.0K | -$124.0K |
| Other noncurrent assets | -$50.0K | $72.0K |
| Accounts payable and accrued expenses | -$399.0K | -$303.0K |
| Amounts due to related parties | -$30.0K | -$29.0K |
| Other current liabilities | -$57.0K | $0 |
| Operating lease payments | -$122.0K | -$850.0K |
| Net cash used in operating activities | -$4.7M | -$9.6M |
| Proceeds from sale of property and equipment | $0 | $334.0K |
| Proceeds from sale of investments | $0 | $5.0M |
| Proceeds from sale of intangible assets | $750.0K | $4.0M |
| Cash paid related to sale of GoodWheat | $0 | -$2.0M |
| Purchases of property and equipment | $0 | -$16.0K |
| Net cash provided by investing activities | $750.0K | $7.3M |
| Proceeds from ESPP purchases | $6.0K | $9.0K |
| Net cash provided by financing activities | $6.0K | $9.0K |
| Net decrease in cash and cash equivalents | -$4.0M | -$2.3M |
| Right of use assets obtained in exchange for new operating lease liabilities | $0 | $86.0K |
| Note receivable recognized from sale of GoodWheat | $0 | $5.7M |
| Fair value of Above Food Ingredients, Inc. common stock received | $3.1M | $0 |
Compare Arcadia Biosciences (United States) with another company
Timeline
- 2002Founded Founded1
Recent filings
- Sep 30, 2026SCHEDULE 13G
- Sep 30, 2026S-8
- Sep 15, 20268-K
- Sep 14, 20264
- Sep 14, 20264
- Sep 14, 20264
- Sep 14, 20264
- Sep 4, 20268-K
- Aug 14, 2026SCHEDULE 13G/A
- Aug 13, 20268-K
- Aug 13, 202610-Q
- Aug 10, 20268-K
- Aug 10, 2026DEF 14A
- Aug 10, 2026ARS
- Jul 31, 2026PRE 14A
Every filing from the last three years, summarized. The full record is on SEC EDGAR.2
Links
- Websitewww.arcadiabio.com1
- X (Twitter)x.com/arcadiaag1
- WikipediaArcadia Biosciences
- WikidataQ30285756
- SEC EDGARCIK 1469443
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13